Logic of Technological Innovation
Solid tumors of are an immense societal burden
- Solid tumors are abnormal masses of tissue that do not contain cysts or liquid areas
Benign (not cancer)
Malignant (cancer)
- Different cancers are named for various types of cells
- Late diagnosis and deficient prognosis together impact patient mortality and raise healthcare costs
Tumor location with MRI using GBCA is standard care
- GBCA = Gadolinium based contrast agent
- 1988 = first clinical MRI scan in patients
Enhanced MRI with GBCAs is a major global market
- GBCAs provide MRI contrast
- localization of lesions for cancer diagnosis
- no information on pathology (i.e., no physiology)
- limited capability for prognosis of cancer therapy
- repeated scans with GBCAs are discouraged due to toxicity
- GBCAs comprise a $2 billion market
- Bayer ( * Magnevist, Gadavist)
- Bracco (MultiHance, ProHance)
- Daiichi Sankyo (Luminity, Mangafodipir)
- GE Healthcare (Omniscan, Clariscan)
- Guerbet ( * Dotarem, Lipiodol)
Our Services
Evolution of various technologies in the last 35 years
Essential to revolutionize MRI contrast agent design
•
Scientific rationale for innovation of smart MRI probe
- The smart MRI probe will sense ionic imbalances (of H+ and Na+) associated with metabolic dysfunctions
- The smart MRI probe will be designed for human use